Source comparison
PT-141 vs Cialis for ED: Comparison
Before evaluating which compound fits your protocol, this table outlines the core pharmacological and practical differences that govern patient response. Mechanism MC4R agonist. Central arousal induction via hypothalamic dopamine modulation PDE5 inhibitor. Per
This comparison does not assign a generated winner or score.
- Before evaluating which compound fits your protocol, this table outlines the core pharmacological and practical differences that govern patient response.
- Mechanism
- MC4R agonist. Central arousal induction via hypothalamic dopamine modulation
- PDE5 inhibitor. Peripheral vasodilation via cGMP accumulation in penile smooth muscle
- Entirely distinct pathways; combination therapy addresses both arousal and vascular components
- Route of Administration
- Subcutaneous injection, 1.75mg per dose
- Oral tablet, 5–20mg per dose
- Injection compliance is lower but avoids first-pass metabolism
- Onset Time
- 45–90 minutes
- 30–60 minutes
- Cialis faster for predictable timing
- Duration of Effect
- 6–12 hours
- Up to 36 hours
- Cialis offers extended spontaneity window
- Primary Indication
- Low libido, psychogenic ED, arousal deficits
- Vascular ED, organic erectile dysfunction from metabolic or cardiovascular causes
- Match mechanism to etiology; mismatched use produces minimal benefit
- Efficacy in Vascular ED
- Limited. Doesn't address nitric oxide or cGMP pathways
- High. 60–81% success rate in controlled trials
- PT-141 not effective as monotherapy for true vascular insufficiency
- Adverse Event Profile
- Nausea (40%), flushing (20%), injection site reactions
- Headache (15%), flushing (10%), nasal congestion, rare visual disturbances
- PT-141 GI side effects are dose-limiting for some patients
- Regulatory Status
- FDA-approved for female hypoactive sexual desire disorder; off-label for male ED
- FDA-approved for male ED and benign prostatic hyperplasia
- Tadalafil has broader approved indications and longer safety track record